Zhenlong Zhao, Boqiang Fan, Junfeng He, Ying Zhou, Songsong Wu, Shurong Wang, Gang Dong, Jianqin Guo, Ying Wei, Jie Wu, Shiliang Cao, Yan Li, Ming'an Yu
{"title":"Thermal ablation versus surgical resection for follicular thyroid neoplasm: a multicenter study.","authors":"Zhenlong Zhao, Boqiang Fan, Junfeng He, Ying Zhou, Songsong Wu, Shurong Wang, Gang Dong, Jianqin Guo, Ying Wei, Jie Wu, Shiliang Cao, Yan Li, Ming'an Yu","doi":"10.1080/02656736.2025.2539177","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To compare thermal ablation (TA) and surgical resection (SR) for follicular thyroid neoplasm (FTN) with F-TIRADS score lower than 12 points in terms of overall, 1-, 3-, and 5-year progression-free survival rates and complication rates.</p><p><strong>Materials and methods: </strong>In this retrospective study, 692 patients with FTN treated by TA or SR across 9 centers between January 2014 and June 2023 were included. The primary outcomes were overall and 1-, 3-, and 5-year progression-free survival rates and complication rates.</p><p><strong>Results: </strong>As a result, 258 patients (median age: 43.5 years, 205 females) in the TA group and 135 patients (median age: 49 years, 101 females) in the SR group were followed for a median of 23 months and 25 months, respectively. TA resulted in shorter incision length, procedure durations and hospitalization (all <i>p</i> < 0.001). There was no evidence of differences in overall, 1-, 3-, or 5-year progression-free survival rates (all <i>p</i> > 0.05) between TA and SR (5-year: 98.6% vs. 99.4%, <i>p</i> = 0.31). Permanent hoarseness (8.1% [15/135], <i>p</i> < 0.001), permanent hypoparathyroidism (0.7% [1/135], <i>p</i> = 0.74), transient hypoparathyroidism (3.0% [4/135], <i>p</i> = 0.02) and the need for lifelong hormone replacement therapy (64.4% [87/135], <i>p</i> < 0.001) were encountered only in the SR group.</p><p><strong>Conclusion: </strong>There was no evidence of difference in progression-free survival rates between TA and SR for FTN with F-TIRADS score lower than 12 points, and TA resulted in fewer complications and no need of hormone replacement therapy. Therefore, TA is a feasible alternative for selected patients with FTN.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2539177"},"PeriodicalIF":3.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/02656736.2025.2539177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To compare thermal ablation (TA) and surgical resection (SR) for follicular thyroid neoplasm (FTN) with F-TIRADS score lower than 12 points in terms of overall, 1-, 3-, and 5-year progression-free survival rates and complication rates.
Materials and methods: In this retrospective study, 692 patients with FTN treated by TA or SR across 9 centers between January 2014 and June 2023 were included. The primary outcomes were overall and 1-, 3-, and 5-year progression-free survival rates and complication rates.
Results: As a result, 258 patients (median age: 43.5 years, 205 females) in the TA group and 135 patients (median age: 49 years, 101 females) in the SR group were followed for a median of 23 months and 25 months, respectively. TA resulted in shorter incision length, procedure durations and hospitalization (all p < 0.001). There was no evidence of differences in overall, 1-, 3-, or 5-year progression-free survival rates (all p > 0.05) between TA and SR (5-year: 98.6% vs. 99.4%, p = 0.31). Permanent hoarseness (8.1% [15/135], p < 0.001), permanent hypoparathyroidism (0.7% [1/135], p = 0.74), transient hypoparathyroidism (3.0% [4/135], p = 0.02) and the need for lifelong hormone replacement therapy (64.4% [87/135], p < 0.001) were encountered only in the SR group.
Conclusion: There was no evidence of difference in progression-free survival rates between TA and SR for FTN with F-TIRADS score lower than 12 points, and TA resulted in fewer complications and no need of hormone replacement therapy. Therefore, TA is a feasible alternative for selected patients with FTN.